Malignant Neoplasm of the Endometrium B045

Current RMA Instruments:

Changes from previous Instruments:

 ICD Coding:

• ICD-10-AM Codes: C54.1

Brief description

Malignant neoplasm of the endometrium refers to cancer arising from the endometrial lining of the uterus. It is the most common gynaecological cancer in developed countries. Most cases occur in post-menopausal women, typically over the age of 50 years old. 

Confirming the diagnosis

Diagnosis requires histological examination of tissue obtained from endometrial biopsy, a dilation and curettage procedure, or surgical removal. While the treating doctor can reasonably confirm the diagnosis, obtaining the histopathology report may be important for clarity and diagnostic certainty. 

The assessment and management of this condition will usually involve consultation with a gynaecologist and/or gynaecologist oncologist. 

Diagnoses covered by SOP

• Adenoacanthoma of the endometrium
• Adenocarcinoma of the endometrium
• Adenosquamous, clear cell and papillary serous carcinoma of the endometrium
• Carcinoma-in-situ of the endometrium
• Carcinosarcoma of the endometrium
• Malignant mesodermal mixed tumour of the endometrium

Conditions excluded from SOP

• Hodgkin's lymphoma of the endometrium *
• Leiomyoma (fibroid) of the uterus #
• Malignant neoplasm of the cervix *
• non-Hodgkin's lymphoma of the endometrium *
• soft tissue sarcoma of the endometrium *

* another SOP applies  - the SOP has the same name unless otherwise specified

^# non-SOP condition

Clinical onset

This condition often presents with non-specific symptoms, such as post-menopausal bleeding or abnormal uterine bleeding in pre-menopausal women, pelvic pain or pressure or fatigue. 

The clinical onset is defined as the first appearance of clinical signs consistent with malignant neoplasm of the endometrium, as documented by the treating doctor, and subsequently confirmed by histopathology examination. 

Clinical worsening

For clinical worsening, the SOP only has an 'inability to obtain appropriate clinical management factor.' Failure to undergo timely treatment could result in permanent worsening in the form of local invasion/destruction of normal tissue, metastasis or death from the disease. Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion.